AI-powered platform for autologous iPSC manufacturing
Induced pluripotent stem cell (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CERTAINTY
A CEllulaR immunoTherapy virtuAl twin for personalIsed cance...
10M€
Cerrado
TED2021-132296A-C53
BIOFISICA COMPUTACIONAL PARA LA DIGITALIZACION DE LEUCEMIA I...
133K€
Cerrado
Cilia-AI
European Training Program for Deconvolution of Multi-scale C...
Cerrado
SICTEC
Single Cell Technologies for SMEs
1M€
Cerrado
NIMSB
NOVA Institute for Medical Systems Biology
15M€
Cerrado
PTA2023-022862-I
Servicio en cultivos celulares pluripotentes, análisis y cri...
52K€
Cerrado
Información proyecto AiPSC
Duración del proyecto: 47 meses
Fecha Inicio: 2022-09-01
Fecha Fin: 2026-08-31
Líder del proyecto
MIDA BIOTECH BV
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Induced pluripotent stem cell (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy associated disease and defective tissues, is unprecedented in history. However, the current methodologies prohibit standardized production of person's own (autologous) iPSCs, hence rejection is taking place and the therapeutic promise is not fulfilled. Our consortium seeks to develop a new technology that will enable the mass production of personalized iPSCs for autologous adoptive cancer immunotherapies, hematopoietic stem cell transplantation, and tissue regeneration.The consortium will for the first time create an artificial intelligence (AI) guided microfluidic device that standardizes the GMP production of autologous iPSCs fast and at a fraction of the current cost. Moreover, it will conduct cutting-edge single cell genomics and bioinformatics research of iPSC to identify clones of highest quality, and develop a database that will be the basis for AI software to select clones that meet clinical standards. The consortium comprises of experts in microfluidics engineering process automation for cell therapies, stem cell molecular biology and bioinformatics, GMP production, and AI modelling. The participating companies, startups, and universities are amongst the leading in Europe, and will promote the positions of female and early career participants from developed and developing European countries. The consortium aims to reach TRL3 prototype stage, and have created a concrete exploitation plan to develop the technology further for implementation in cancer therapy and regenerative medicine. Altogether, we propose to create revolutionary technology for low cost, fast, and standardized automated mass production of autologous iPSCs, which holds the potential to enable numerous new therapies and making them accessible to the public.